About Axovan
Axovan is a company based in Allschwil (Switzerland) founded in 2000 was acquired by Actelion in September 2003. Axovan has raised $23.31 million across 2 funding rounds from investors including Actelion, Atlas Venture and Heidelberg Innovationsfonds Management. Axovan operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Allschwil, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Axovan
Axovan has successfully raised a total of $23.31M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $18.4 million completed in April 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Axovan
Axovan has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Actelion, Atlas Venture and Heidelberg Innovationsfonds Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
Locked | Locked | Locked |
Investor details for Axovan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axovan
Investment portfolio details for Axovan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Axovan
Detailed financials for Axovan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Axovan Comparisons
Peer comparison for Axovan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Axovan
Axovan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of Axovan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Axovan
Complete news archive for Axovan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axovan
Axovan was founded in 2000.
Axovan is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Axovan is a funded company, having raised a total of $23.31M across 2 funding rounds to date.
Axovan AG was a drug development company specializing in G Protein-Coupled Receptors (GPCRs). The company had a fully functional drug discovery platform and a growing portfolio of drug candidates targeting GPCRs for various indications. At the time of acquisition, its most advanced project is a drug called clazosentan (aims to prevent cerebral vasospasm, or sharp contractions of the blood vessels, which can occur after a certain type of brain hemorrhage), which it licensed from Roche Holding AG. The drug was in Phase II of clinical testing, which monitors effectiveness and safety on a limited number of patients, and the same class as Actelions Tracleer.
Axovan's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Axovan has 3 investors. Key investors include Actelion, Atlas Venture, and Heidelberg Innovationsfonds Management.